A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Latest Information Update: 18 Apr 2023
At a glance
- Drugs Trilaciclib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRESERVE 4
- Sponsors G1 Therapeutics
- 21 Apr 2022 This trial has been discontinued in Spain, according to European Clinical trials database record.
- 03 Mar 2022 This trial has been discontinued in Poland and Italy, according to European Clinical trials database record.
- 17 Nov 2021 Status changed from recruiting to active, no longer recruiting.